- $5.08m
- $3.29m
- $6.16m
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:07 PM
NASDAQ RESUMED AT 12:31 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:26 PM
NASDAQ RESUMED AT 11:11 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:06 AM
NASDAQ RESUMED AT 09:45 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:40 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Bioaffinity Technologies Announces 1-For-15 Reverse Stock Split Effective At The Open Of Trading On August 24, 2026
Brief: Bioaffinity Technologies And Avmedical Announce Nationwide Federal Healthcare Distribution Agreement For Cypath Lung
bioAffinity Technologies Q2 revenue rises on CyPath Lung demand
Brief: bioAffinity Technologies Q2 Net Income USD -3.4 Million
Brief: Bioaffinity Technologies - Offers 2.63 Million Shares Of Common Stock - SEC Filing
Brief: Bioaffinity Technologies Inc - Q1 2026 Net Loss $3.6 Million Or $0.81 Per Share
Brief: Bioaffinity Announces Validation Study For Lung Cancer Test
Brief: Bioaffinity Technologies Announces About $1.8 Million Registered Direct Financing Of Common Stock